Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 139 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atorvastatin Placebo Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

NCT03351998
View directory record Official record
Conditions
Mitochondrial Diseases
Interventions
Lipitor 20Mg Tablet, Lipitor 80Mg Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
35 Years to 65 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
2
States / cities
Kansas City, Kansas • Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 29, 2026, 4:35 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Atorvastatin on Myonecrosis

NCT00344019
View directory record Official record
Conditions
Coronary Disease
Interventions
Placebo Oral Tablet, Atorvastatin 80mg, Screening
Drug · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2018 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Statin Medications on Muscle Performance (The STOMP Study)

NCT00609063
View directory record Official record
Conditions
Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
20 Years and older
Enrollment
420 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
3
States / cities
Hartford, Connecticut • Storrs, Connecticut • Amherst, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 9, 2012 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

NCT01350141
View directory record Official record
Conditions
Hypercholesterolemia, Dyslipidemia
Interventions
Placebo, PF-04950615 (RN316)
Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Garden Grove, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Study of Atorvastatin Versus Placebo to Reduce Cardiopulmonary Complications After Thoracic Surgery

NCT00375518
View directory record Official record
Conditions
Thoracic Surgery
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Withdrawn Not applicable Interventional

Statin Therapy To Limit Cognitive Dysfunction After Cardiac Surgery

NCT01186289
View directory record Official record
Conditions
Neurocognitive Dysfunction
Interventions
atorvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 14, 2015 · Synced Oct 29, 2026, 4:35 AM EDT
Recruiting Phase 1 Interventional

Novel Approaches for Improving Vascular Function in Veterans With HFpEF

NCT06312748
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Inflammation
Interventions
L-Citrulline, Placebo for L-Citrulline, BH4, Placebo for BH4, Atorvastatin, Placebo for Atorvastatin
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 29, 2026, 4:35 AM EDT
Terminated Phase 3 Interventional Results available

Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

NCT00252967
View directory record Official record
Conditions
Atrial Fibrillation, Inflammation
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

NCT02135029
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Bococizumab (PF-04950615;RN316), Atorvastatin, Placebo for Bococizumab (PF-04950615;RN316), Placebo for atorvastatin
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Denver, Colorado • Bridgeport, Connecticut • Lakeland, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2017 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease

NCT01732718
View directory record Official record
Conditions
Sickle Cell Disease, Sickle Cell Nephropathy
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Statin Therapy in Heart Failure: Potential Mechanisms of Benefit

NCT00233480
View directory record Official record
Conditions
Heart Failure, Congestive
Interventions
atorvastatin, placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2020 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin

NCT01492361
View directory record Official record
Conditions
Cardiovascular Diseases
Interventions
AMR101, Placebo, Statin therapy
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
45 Years and older
Enrollment
8,179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
176
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 154 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS

NCT00559962
View directory record Official record
Conditions
Hyperlipidemia
Interventions
AEGR-733, placebo, AEGR-733 and atorvastatin, AEGR-733 and fenofibrate, AEGR-733 and ezetimibe
Drug
Lead sponsor
Aegerion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2018 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia

NCT02714569
View directory record Official record
Conditions
Dyslipidemias
Interventions
LY3202328, Placebo, Atorvastatin, Simvastatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
4
States / cities
Miami, Florida • Lenexa, Kansas • Marlton, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL

NCT01047683
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo
Drug
Lead sponsor
Amarin Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
18
States / cities
Sacramento, California • Golden, Colorado • Miami, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Evaluate Carotid Artery Plaque Composition by Magnetic Resonance Imaging in People Receiving Cholesterol Medication

NCT00715273
View directory record Official record
Conditions
Coronary Artery Disease, Carotid Artery Diseases, Atherosclerosis
Interventions
Atorvastatin, Niacin, Colesevelam, Placebo Niacin, Placebo Colesevelam
Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years to 70 Years
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2019
U.S. locations
4
States / cities
Los Angeles, California • Boise, Idaho • Seattle, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of LY2484595 in Patients With High LDL-C or Low HDL-C

NCT01105975
View directory record Official record
Conditions
Dyslipidemia
Interventions
LY2484595, Atorvastatin, Simvastatin, Rosuvastatin, Placebo for LY2484595, Placebo for Statins
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Fayetteville, Arkansas • San Diego, California • Spring Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2018 · Synced Oct 29, 2026, 4:35 AM EDT
Active, not recruiting Phase 2 Interventional

Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis

NCT04767984
View directory record Official record
Conditions
Colorectal Carcinoma, Ulcerative Colitis
Interventions
Atorvastatin Calcium, Biopsy of Colon, Biospecimen Collection, Placebo Administration, Questionnaire Administration
Drug · Procedure · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
Chicago, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)

NCT01617655
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo (for alirocumab), Lipid Modifying Therapy (LMT)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
14
States / cities
Bell Gardens, California • Newport Beach, California • Northridge, California + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2016 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 4 Interventional

Caduet in an Untreated Subject Population

NCT00332761
View directory record Official record
Conditions
Hypertension, Dyslipidemia
Interventions
Caduet
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
34
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood

NCT00639158
View directory record Official record
Conditions
Dyslipidemias, Coronary Heart Disease, Combined (Atherogenic) Dyslipidemia, Mixed Dyslipidemia
Interventions
ABT-335, placebo, atorvastatin, ezetimibe
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
543 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
118
States / cities
Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Oct 29, 2026, 4:35 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

NCT02227784
View directory record Official record
Conditions
Hyperlipidemia
Interventions
Evacetrapib, Atorvastatin, Ezetimibe, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
366 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
61
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 29, 2026, 4:35 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

NCT04262206
View directory record Official record
Conditions
Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Interventions
Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
75 Years and older
Enrollment
20,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
104
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 29, 2026, 4:35 AM EDT
Completed Not applicable Interventional Results available

Short-term Atorvastatin's Effect on Acute Kidney Injury Following Cardiac Surgery

NCT00791648
View directory record Official record
Conditions
Acute Kidney Injury, Post-Operative Delirium, Icu Delirium, Acute Renal Failure, Delirium
Interventions
atorvastatin, placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
653 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Oct 29, 2026, 4:35 AM EDT